- Home
- Structural Heart Disease
Structural Heart Disease
HCM in Review: Highlights of 2022
- 0.25 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments
- Summarise results from ongoing trials with experimental treatments
HCM in Review: Assessing SCD Risk in HCM & Managing HCM With High Risk SCD
- 0.50 AMA PRA Credit
Published:
Learning objectives
- Recall risk factors associated with sudden cardiac death (SCD)
- Recall best practice approaches to prevent SCD according to guidelines and expert insight
- Stratify patients likely to benefit from invasive procedures versus pharmacological treatment
Severe Aortic Stenosis: Stratifying Patients for Lifetime Management
- 1 EBAC
Published:
Learning objectives
- Describe the challenges with lifetime management in severe AS in both a SAVR and TAVI-first scenario
- Summarise clinical evidence for TAVI in low surgical risk patients
- Recall different guideline recommendations for SAVR and TAVI approaches
- Assimilate current clinical knowledge with patient preferences when formulating treatment plans for severe AS patient
Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
- 0.50 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
- Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities
Hypertrophic Cardiomyopathy in Review: Highlights of ACC 2022
- 0.25 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
Getting it Right First Time in Severe Aortic Stenosis - Key insights for Long Term Success
- 1 EBAC
Published:
Learning objectives
- Recall current and predicted trends in TAVI with respect to preserving coronary access
- Consider determining factors for choosing valves in low risk populations
- Discuss solutions for maximising valve durability and haemodynamics and for treating degenerated TAVI
